Rongfeng Fu

Rongfeng Fu

Auto-generated profile, based on publicly available information

Rongfeng Fu

State Key Laboratory of Experimental Hematology, Key Laboratory of Gene Therapy of Blood Diseases, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 288 Nanjing Road, Tianjin, 300020, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2018 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
CLCuicui Lyu
Cuicui Lyu
JSJun Shen
Jun Shen
RWRui Wang
Rui Wang
HGHaihui Gu
Haihui Gu
JZJianping Zhang
Jianping Zhang
LZLei Zhang
Lei Zhang
Replacement therapy for hemophilia remains a lifelong treatment. Only gene therapy can cure hemophilia at a fundamental level. The clustered regularly interspaced short palindromic repeats–CRISPR associated nuclease 9 (CRISPR-Cas9) system is a versatile and convenient genome editing tool which can be applied to gene therapy for hemophilia. A patient’s induced pluripotent stem cells (iPSCs) were generated from their peripheral blood mononuclear cells (PBMNCs) using episomal vectors. The AAVS1-Cas9-sgRNA plasmid which targets the AAVS1 locus and the AAVS1-EF1α-F9 cDNA-puromycin donor plasmid were constructed, and they were electroporated into the iPSCs. When insertion of F9 cDNA into the AAVS1 locus was confirmed, whole genome sequencing (WGS) was carried out to detect the off-target issue. The iPSCs were then differentiated into hepatocytes, and human factor IX (hFIX) antigen and activity were measured in the culture supernatant. Finally, the hepatocytes were transplanted into non-obese diabetic/severe combined immunodeficiency disease (NOD/SCID) mice through splenic injection. The patient’s iPSCs were generated from PBMNCs. Human full-length F9 cDNA was inserted into the AAVS1 locus of iPSCs of a hemophilia B patient using the CRISPR-Cas9 system. No off-target mutations were detected by WGS. The hepatocytes differentiated from the inserted iPSCs could secrete hFIX stably and had the ability to be transplanted into the NOD/SCID mice in the short term. PBMNCs are good somatic cell choices for generating iPSCs from hemophilia patients. The iPSC technique is a good tool for genetic therapy for human hereditary diseases. CRISPR-Cas9 is versatile, convenient, and safe to be used in iPSCs with low off-target effects. Our research offers new approaches for clinical gene therapy for hemophilia.

16 August 2013 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
RFRongfeng Fu
Rongfeng Fu
LZLei Zhang
Lei Zhang
RYRenchi Yang
Renchi Yang

1 September 2014 in Chinese Journal of Hematology
Verified
Journal Article
Closed access
RFRongfeng Fu
Rongfeng Fu
MXMin Xuan
Min Xuan
LZLiyan Zhang
Liyan Zhang
HLHuiyuan Li
Huiyuan Li
TSTiantian Sun
Tiantian Sun
RYRenchi Yang
Renchi Yang
To analyze clinical and molecular characteristics of low-risk essential thrombocythemia (ET) in a large cohort of Chinese patients and to explore risk factors for major thrombosis and treatment strategies. Medical records of patients with an initial diagnosis of ET from March 1982 to May 2012 in our hospital were retrospectively analyzed. A total of 604 low-risk ET patients were enrolled with a median follow-up of 49 months (range:0-338). 43(7.1%) patients experienced major thrombotic events. Cox proportional hazards regression revealed JAK2 V617F mutation (HR=2.279; P=0.035) and cardiovascular risk factors (CVF) (HR=2.541; P=0.006) to be risk factors for total thrombotic events, while only CVF (HR=2.633; P=0.008) was risk factor for arterial thrombosis. None of the evaluated factors was related to venous thrombosis. Patients with both JAK2 V617F mutation and CVF had a worse thrombosis- free survival than those with only one risk factor (P<0.05). In patients with JAK2 V617F or CVF alone, antiplatelet treatment (P=0.016) significantly decreased the risk of thrombosis, while those with both JAK2 V617F and CVF could benefit from cytoreductive agents (P=0.018). Chinese low-risk ET patients have a lower risk of thrombosis than Caucasian low-risk ET patients. JAK2 V617F mutation and CVF are the most significant risk factors for thrombosis. Existence of both risk factors further increases the thrombotic risk. Treatment strategies on low-risk ET patients should be made based on presence or absence of risk factors.

1 August 2014
Verified
Journal Article
Closed access
HLHui-Yuan Li
Hui-Yuan Li
DZDonglei Zhang
Donglei Zhang
XZXian Zhang
Xian Zhang
RFRong-Feng Fu
Rong-Feng Fu
MXMin Xuan
Min Xuan
RYRen-Chi Yang
Ren-Chi Yang

1 September 2014 in Chinese Journal of Hematology
Verified
Journal Article
Closed access
MLMing'En Lyu
Ming'En Lyu
XLXiaofan Liu
Xiaofan Liu
RFRongfeng Fu
Rongfeng Fu
TSTiantian Sun
Tiantian Sun
WLWenjie Liu
Wenjie Liu
RYRenchi Yang
Renchi Yang
To explore the clinical significance, reliability and responsiveness of ITPBAT bleeding grading system for patients with immune thrombocytopenia (ITP). One hundred and eighty-three patients with ITP were assessed by using of ITP-BAT bleeding grading system. Test-retest reliability, responsiveness of ITP-BAT bleeding grading system and association between bleeding grades and platelet counts, age, gender, disease stage were analyzed. Bleeding degree of ITP patients and the platelet count were negatively correlated (r=- 0.744, P0.05 and χ²=3.411, P>0.05). Bleeding grades before and after treatment had more significant difference(Z=-6.61, P<0.01). Scoring consistency of two doctors was 66.1% (κ=0.561), and scoring consistency of the same doctor was 94.7% (κ=0.874). ITP-BAT bleeding grading system in China has good validity and responsiveness, closely related to clinical indicators. It is sensitive to the variation of the hemorrhage in patients. ITP-BAT could be used as a reference index of the treatment, and also be used as an observation index of curative effect.

14 August 2015
Verified
Journal Article
Closed access
XZXian Zhang
Xian Zhang
DZDonglei Zhang
Donglei Zhang
WLWenjie Liu
Wenjie Liu
HLHuiyuan Li
Huiyuan Li
RFRongfeng Fu
Rongfeng Fu
RYRenchi Yang
Renchi Yang